Market research
ANCN Anchiano Therapeutics Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 0.96
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03280X1028
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 0.96
About
About Anchiano Therapeutics Ltd
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ANCN discussion.
5 years, 4 months ago
Anchiano Therapeutics Ltd is currently in a long term uptrend where the price is trading 92.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Anchiano Therapeutics Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 123.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 73.0% to $-2M since the same quarter in the previous year.
Based on the above factors, Anchiano Therapeutics Ltd gets an overall score of 3/5.